Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SHE: 002675)

Market Cap	9.67B
Revenue (ttm)	2.91B
Net Income (ttm)	137.22M
Shares Out	824.60M
EPS (ttm)	0.17
PE Ratio	70.49
Forward PE	37.84
Dividend	0.13 (1.07%)
Ex-Dividend Date	Jun 24, 2024

Volume	1,615,900
Open	11.92
Previous Close	11.70
Day's Range	11.62 - 11.92
52-Week Range	11.33 - 20.15
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C. The company also provides nadroparin calcium, hydrocortisone sodium succinate, chorionic gonadotrophin, and menotropins for...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,333
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002675

Financial Performance

In 2023, Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s revenue was 3.28 billion, a decrease of -8.58% compared to the previous year's 3.58 billion. Earnings were 209.74 million, a decrease of -31.75%.